Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Research & Development (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Research & Development for 7 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 304.36% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, up 138.56% year-over-year, with the annual reading at $7.8 million for FY2025, 138.56% up from the prior year.
  • Research & Development hit $1.8 million in Q4 2025 for Eton Pharmaceuticals, up from $1.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.7 million in Q2 2025 to a low of -$871000.0 in Q4 2024.
  • Historically, Research & Development has averaged $1.2 million across 5 years, with a median of $915000.0 in 2021.
  • Biggest five-year swings in Research & Development: tumbled 183.19% in 2024 and later soared 304.36% in 2025.
  • Year by year, Research & Development stood at $681000.0 in 2021, then skyrocketed by 38.62% to $944000.0 in 2022, then grew by 10.91% to $1.0 million in 2023, then crashed by 183.19% to -$871000.0 in 2024, then skyrocketed by 304.36% to $1.8 million in 2025.
  • Business Quant data shows Research & Development for ETON at $1.8 million in Q4 2025, $1.1 million in Q3 2025, and $3.7 million in Q2 2025.